Category Archives: Psoriasis

Read on to find out the latest about AbbVie, GBT, a small global biopharma company with a potentially monster drug, and impactful studies from the world of COVID-19 research.

AbbVie Stock Trips Upon FDA Delay of Rinvoq

AbbVie and its investors will have to practice the virtue of patience as the Food and Drug Administration (FDA) extended its review of upadacitinib, or Rinvoq, for the treatment of adults with active psoriatic arthritis.

The top U.S. regulator made the decision to extend the supplemental New Drug Application (sNDA) on Wednesday, requesting further information and an updated benefit-risk profile for this indication. AbbVie will have three months to compile the data, putting the new action date close to the end of Q2 2021.

Rinvoq, an oral, once-daily selective, and reversible JAK inhibitor being studied for the treatment of many immune-mediated inflammatory diseases was approved in 2019 for rheumatoid arthritis.

It is one of two medicines under development that AbbVie investors are betting on to allay the loss when patent protection for Crohn's disease drug, Humira, expires in 2023. Analysts believe that expanded authorization for Rinvoq would go a long way toward that goal.

"We remain confident in the sNDA and are committed to working with the FDA to bring upadacitinib to patients living with psoriatic arthritis and other immune-mediated diseases," said AbbVie vice chairman and president, Michael Severino, M.D.

AbbVies other long-term hopeful to replace the lost revenue from Humira is Skyrizi (risankizumab-rzaa), a treatment for moderate-to-severe plaque psoriasis. AbbVie is teamed up on this one with Boehringer Ingelheim Pharmaceuticals, Inc., and leads the development and commercialization worldwide.

Apellis, the Little Biopharma that Could Transform PNH Treatment

Apellis Pharmaceuticals, a small clinical-stage biopharmaceutical company located in Watertown, Massachusetts, is hoping to leap headfirst into an uphill battle against Alexion Pharmaceuticals soon to beAstraZenecas Soliris and successor, Ultomiris, with its C3 drug for rare paroxysmal nocturnal hemoglobinuria (PNH).

PNH is a rare, acquired life-threatening disorder that occurs when this out-of-control cascade leads to the destruction of red blood cells, blood clots, and impaired bone marrow function.

Systemic Pegcetacoplan (APL-2), which has a PDUFA date of May 14, targets complement proteins centrally at the level of the C3 protein and aims to regulate the uncontrolled or excessive complement cascade that manifests in debilitating diseases in hematology, ophthalmology, nephrology, and neurology.

Swedish Orphan Biovitrum AB, Sobi, holds global co-development and ex-US commercialization rights to Pegcetacoplan.

Soliris (Eculizumab) is a first-in-class C5 complement inhibitor that reduces both the destruction of red blood cells and the need for blood transfusion in patients with PNH.

Yesterday, the New England Journal of Medicine (NEJM) published a comparison of Phase IIIPEGASUS study results of pegcetacoplan comparing the two treatments.

The study demonstrated the superiority of pegcetacoplan in improving hemoglobin levels, along with improvements in key clinical outcomes in adult PNH patients who suffered from persistent anemia after treatment with eculizumab.

The results published in the NEJM state that pegcetacoplan met the studys primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.

Meaningful improvements in fatigue were also noted, all inspiring hope for an improved standard of care in PNH.

The data published in the New England Journal of Medicine underscore the potential of pegcetacoplan to be a significant advancement for people living with PNH, said Peter Hillmen, M.B., Ch.B., Ph.D., professor of experimental hematology at Leeds Teaching Hospitals NHS Trust and PEGASUS study author. There is still a need for new treatments because many patients with PNH treated with C5 inhibitors today remain anemic, resulting in moderate to severe fatigue, with a proportion continuing to require transfusions.

Apellis Chief Medical Officer, Federico Grossi, M.D., Ph.D., also reflected on the results:

The PEGASUS study results demonstrate that, if approved, pegcetacoplan has the potential to elevate the standard of care for PNH by providing more complete disease control. We are working to quickly bring this potential new treatment to PNH patients and to advance development of pegcetacoplan for many other serious, complement-driven diseases.

Getting to The Heart of COVID-19 Fatalities

Further insight is beginning to emerge into COVID-19s most lethal mechanisms of action. The latest? A study showing that three-quarters of people who died from the illness were found to have the SARS-CoV-2 virus in their hearts.

There is a debate surrounding whether heart damage including elevated levels of troponins, inflammation of the sac surrounding the heart, and inflammation of the muscle itself are caused directly by the virus or the overactive immune response it elicits.

The study, published yesterday in Modern Pathology, in which scientists utilized in situ hybridization and NanoString transcriptomic profiling to study the hearts of 41 victims of the virus, revealed its existence in 30 of them.

Unlike the more common real-time polymerase chain reaction (RT-PCR), this approach does not have to make DNA copies first and can identify viral RNA even after it is broken down into smaller pieces. The team also analyzed about 1,000 pieces of heart tissue, which James Stone, a cardiovascular pathologist at Massachusetts General Hospital and contributing scientist, stated is double the amount of most studies.

Stone explained that chemicals used in RT-PCR can break down the RNA, leaving the virus undetectable in tissues.

Despite the intensive study, it is still unclear whether the damage was inflicted by a direct attack on the heart, as most of the cardiac cells affected were immune cells, allowing for the possibility that SARS-CoV-2 could have traveled from another part of the body.

Still, it could help to paint a picture of why the steroid, dexamethasone, is so effective in some patients and thus bring more clarity to the treatment landscape. Stone said that the virus was only found in 50% of patients who were treated with the drug as opposed to 90% who did not enjoy its potential anti-inflammatory benefits.

Could an Old Leprosy Drug Provide New Hope in COVID-19?

An international alliance of scientists is gung-ho on the potential of repurposing leprosy mainstay, clofazimine, as a treatment for COVID-19.

The researchers, from Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong published results from a study in Nature on Tuesday showing that clofazimine significantly reduced viral load and shedding in hamsters infected with the SARS-CoV-2 virus.

Clofazimine was also shown to have a synergistic effect when used in combination with Gilead Sciences remdesivir, which is currently FDA approved for hospitalized COVID-19 patients.

Adding to its potential in the global fight against COVID-19, Clofazimine, which is included in the World Health Organizations List of Essential Medicines, is also attractively affordable.

Clofazimine is an ideal candidate for a COVID-19 treatment. It is safe, affordable, easy to make, taken as a pill, and can be made globally available, said study co-senior author, Professor Sumit Chandra, Ph.D., director of the immunity and pathogenesis program at Sanford Burnham Prebys. We hope to test clofazimine in a Phase II clinical trial as soon as possible for people who test positive for COVID-19 but are not hospitalized.

GBT Adds More Punch to Sickle Cell Disease Portfolio

Global Blood Therapeutics (GBT), born in 2011 with the goal of transforming the treatment and care of sickle cell disease, announced Tuesday that it has added two novel small molecules from Sanofi S.A. to its pipeline.

Under the agreement, GBT will hold worldwide in-license rights to the two early-stage research programs, one which is aiming for a novel anti-sickling mechanism, while the other takes a new approach to reduce inflammation and oxidative stress. The two programs are the brainchildren of Sanofis Bioverativ subsidiary.

GBT hopes that the mechanisms, while distinct, may complement its Oxbryta (voxelotor) tablets which are designed to block sickle hemoglobin polymerization, the root cause of sickle cell disease, and won accelerated approval in 2019.

We envision a future in which sickle cell disease is a well-managed condition with the potential for a functional cure in the form of patient-friendly oral therapies. As we work toward this vision and our goal to transform the treatment and care of people living with this devastating disease, we are advancing our robust internal research programs with disease-modifying potential while continually exploring partnership opportunities across a variety of mechanisms, said Jung E. Choi, chief business and strategy officer of GBT. These novel discovery programs represent promising approaches that we believe may have the potential to lead to meaningful improvements for patients.

Excerpt from:
ICYMI: A Closer Look at News You Might Have Missed This Week - BioSpace

Dry skin is more common in the winter than in the warmer months. The changes in humidity and temperature at this time of the year can irritate the skin.

Dry skin can affect many people during the winter, and the severity of the symptoms can vary significantly. Various treatments can replenish the moisture of the skin and relieve the symptoms. People can also take certain steps to prevent the skin from becoming dry.

This article looks at dry winter skin in more detail, including its causes, symptoms, prevention, and treatment.

Winter brings changes in humidity and temperature that create perfect conditions for causing dry skin, also known as xerosis.

The outermost layer of the skin is called the epidermis. The thin outer surface of the epidermis is the stratum corneum, also known as the skin barrier.

A combination of lipids and dying or dead skin cells makes up the skin barrier. The skin barrier forms a layer of protection that prevents harmful toxins from entering the body. When the skin barrier sustains damage, the skin appears dry or irritated.

Moisture is essential for the skin barrier to perform well. Research has shown that there is less moisture in the skin during winter than in the summer, as well as fewer lipids in the skin barrier. These differences contribute to dryness and irritation.

During the winter months, people often turn their indoor heating up high, which reduces humidity and affects how much moisture is available to the skin.

At the same time, the cold outdoor weather, harsh winds, and rain can strip the skin of its natural, moisturizing oils.

Taking hot baths or showers can also damage the surface of the skin, leading to dryness, according to the Baylor College of Medicine. Using harsh soaps and rubbing the skin vigorously when drying it can contribute to skin damage.

The level of moisture in the skin also varies with age, gender, ethnicity, and environmental factors. Other medical conditions can also contribute to dry skin.

Dryness that results from damage to the skin barrier during winter can lead to:

People may experience several of these symptoms at the same time. The right treatment should reduce their severity.

Dry and damaged skin needs moisture replenishment. It is best to keep a skin care regimen as simple as possible when treating dry skin. A simple regimen avoids overloading the skin with unnecessary products, such as toners, serums, and heavy makeup.

Using a moisturizer is the best way to rehydrate the epidermis and prevent water loss from the skin. Thick, greasy moisturizers without perfumes are generally the best option. Thinner gels, lotions, and creams can cause stinging when a person uses them on irritated skin.

Moisturizers containing emollients, which include linoleic, linolenic, and lauric acids, can help smooth the surface of the skin. They fill the spaces between skin cells where there has been a loss of moisture.

Humectants in moisturizers help attract moisture to the skin. Examples of humectants include:

Other ingredients, such as lanolin, silicone, and mineral oil, help seal moisture into the skin. They also form a protective barrier to reduce damage from environmental factors.

According to the American Academy of Dermatology Association, it is very important to apply moisturizer as soon as possible after patting the skin dry following a shower or bath. This approach will seal in as much moisture as possible.

When the seasons start to change, people can avoid getting dry winter skin by taking the following steps:

The use of home remedies can improve most cases of dry skin. If they have no effect, a person can contact a healthcare professional, such as a pharmacist, doctor, or dermatologist. These professionals can prescribe the right products or recommend next steps.

Dry winter skin is not an inevitable consequence of the coldest season. Being conscious of the skin barrier and what it needs to stay healthy can help people take the necessary steps to prevent this uncomfortable condition.

The rest is here:
Winter dry skin: Causes, treatment, and more - Medical News Today

DataIntelo has included a latest report on the Global Psoriasis Drug Market into its archive of market research studies. The report is an amalgamation of detailed market overview based on the segmentations, applications, trends and opportunities, mergers and acquisitions, drivers, and restraints. The report showcases the current and forthcoming technical and financial details of the Psoriasis Drug market. The research study attracts attention to a detailed synopsis of the market valuation, revenue estimation, and market statistics. The study on the emerging trends in the global and regional spaces on all the significant components, such as market capacity, cost, price, demand and supply, production, profit, and competitive landscape. The report also explores all the key factors affecting the growth of the global market, consisting of the demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Some of the major companies that are covered in this report:

*Note: Additional companies can be included on request

Get a free exclusive sample report of Psoriasis Drug market @ https://dataintelo.com/request-sample/?reportId=88617

Impact of COVID-19

The report also talks about the impact of the ongoing global crisis i.e., COVID-19 on the Psoriasis Drug market and explains how the future is going to unfold for the global market. Our analysts have researched thoroughly about the effects of the pandemic on the global economy. The outbreak has directly affected production and demand disrupted the demand and supply chain. The report also computes the financial impact on firms and financial markets. DataIntelo has accumulated insights from several delegates of the industry and got involved in the primary and secondary research to offer the clients data & strategies to combat the market challenges during and after the COVID-19 pandemic.

Highlights of the report:

Our research analysts who are the building blocks of the company have worked extensively to fabricate the research report which will give that extra edge to our clients business in the competitive market. The market research report can be customized as per you and your needs. This means that DataIntelo can cover a particular product, application, or can offer a detailed analysis in the report. You can also buy a separate report for a specific region.

You can buy the complete report in PDF format: @ https://dataintelo.com/checkout/?reportId=88617

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Applications:

By Types:

By Regions:

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is integrated into the report is the regional analysis to assess the global presence of the Psoriasis Drug market. You can also opt for a yearly subscription of all the updates on the Psoriasis Drug market.

If you have any questions on this report, feel free to reach us! @ https://dataintelo.com/enquiry-before-buying/?reportId=88617

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Psoriasis Drug Market Overview

Global Psoriasis Drug Market Analysis and Forecast by Type

Global Psoriasis Drug Market Analysis and Forecast by Application

Global Psoriasis Drug Market Analysis and Forecast by Sales Channel

Global Psoriasis Drug Market Analysis and Forecast by Region

North America Psoriasis Drug Market Analysis and Forecast

Latin America Psoriasis Drug Market Analysis and Forecast

Europe Psoriasis Drug Market Analysis and Forecast

Asia Pacific Psoriasis Drug Market Analysis and Forecast

Asia Pacific Psoriasis Drug Market Size and Volume Forecast by Application

Middle East & Africa Psoriasis Drug Market Analysis and Forecast

Competition Landscape

Avail exclusive discount on this report @ https://dataintelo.com/ask-for-discount/?reportId=88617

About DataIntelo:

DataIntelo has a vast experience in making customized market research reports in a number of industry verticals. We strive for complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. Our team makes sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Original post:
Psoriasis Drug Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis- AbbVie, Johnson &...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced an interview with CEO Dr. Pnina Fishman will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, March 20th, at 7 p.m. local time in 73M homes across the United States. The RedChip Money Report also airs on Bloomberg International in Europe in 100M homes at 6 pm local time on Sundays.

In the exclusive interview, Dr. Fishman discusses the Companys upcoming milestones, updates on the pipeline of proprietary small molecule drugs addressing inflammatory, cancer and liver diseases.

To view the interview segment, please visit: https://youtu.be/T6ccv539s4I

The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Piclidenoson

Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. It is currently being evaluated in a multinational Phase III study as a treatment for moderate to severe psoriasis and a Phase II U.S. study for the treatment of moderate to severe COVID-19.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: http://www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fites expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should or anticipate or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fites authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fites actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fites actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fites filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Continue reading here:
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report - Business Wire

What is Psoriasis?

Psoriasis is a chronic disorder causing red, scaly patches on the skin. It usually occurs on the limbs, trunk, and scalp but can show up on other parts of the body as well. It is not contagious but it can flare up causing the symptoms to get worse. The rash associated with psoriasis goes through cycles of improvement before it gets worse. Psoriasis is usually the result of a problem with the immune system. It is most likely to occur in members of the same family. At times, psoriasis can be disfiguring, uncomfortable, and even painful.

Symptoms of psoriasis appear as red, thickened areas of the skin with silvery scales. It most often appears on the scalp, elbows, knees, legs, arms, genitals, nails, palms, and lower back. The skin usually replaces itself after about a month. When psoriasis is present, the process speeds up and the skin is replaced in 3-4 days causing the skin cells to multiply quickly and accumulate on the surface in silvery scales. Psoriasis comes in many forms. Each differs in severity, duration, location, shape, and pattern of the scales. The most common form, called plaque psoriasis, begins with little red bumps. Gradually these become larger, and scales form.

Unfortunately, there is no cure for psoriasis but there are many different psoriasis treatments available that can clear the symptoms and bring relief. Your doctor may prescribe medications applied directly to the skin. These contain cortisone compounds, synthetic vitamin D analogs, retinoids, tar, or anthralin used to ease the discomfort caused by the skin patches. Other types of treatment include coal tar, Goeckerman treatment, light therapy, ultraviolet light B (UVB), PUVA, methotrexate, cyclosporine, and biologic agents. Controlling triggers that bring on bouts of psoriasis, such as stress, and taking care of your skin will help keep symptoms in control. The goal is to reduce inflammation and to control shedding of the skin. Moisturizing creams and lotions loosen scales and help control itching.

Visit link:
Psoriasis Specialist - Katy, TX & Cypress, TX: Texas ...

Psoriasis is a common and commonly misunderstood disorder. Its not simply itchy, dry skin; according to the National Psoriasis Foundation (NPF), its caused by an immune-system dysfunction that brings on inflammation. Normally, a persons skin cells grow and shed in about a month, but for a person with psoriasis, that process is sped up, taking only about 3 or 4 days, and the result is a build-up of skin cells causing scales and plaque. About 8 million Americans deal with its discomfort every day, says the NPF.

Psoriasis is not curable, but thankfully its very treatable, says Mona Gohara, MD, associate clinical professor of dermatology at the Yale School of Medicine. Theres no need to endure the psychological or physical discomfort that may come along with this conditionseek treatment for it. There are a range of possible treatments, from topical creams and lotions to prescription oral medications. If you start at the bottom of therapeutic pyramid with creams, this may be enough to quell the irritation, says Dr. Gohara.

Some creams and lotions that can ease the dryness and itch are available over the counter; with others, youll need a prescription from a doctor. It takes a bit of trial and error to find what topical treatment may work best for you. Here, some guidance to the most common types of creams and lotions for psoriasis.

This is the active ingredient (approved by the FDA for treating psoriasis) in treatments that can help banish scales by softening them and making the outer layer of skin shed. You can find salicylic acid in many forms (not just lotions/creams/ointments, but also foams, soaps, gels, patches, and more). These treatments are designed to work in combo with others, because getting rid of the scales can help other treatments do their work more efficiently. If its a strong version, salicylic acid can irritate the skin and make hair more likely to break off, and that can lead to temporary hair loss, says the NPF.

The NPF says that these are the most frequently used treatments for psoriasis. Theyre designed to quell inflammation and pump the brakes on the growth of skin cells (this helps sidestep the buildup that produces scales). Steroid treatments come in different strengths; mild ones are available over the counter (OTC) and stronger types require a prescription. Generally, the stronger ones are needed for elbows, knees, and other hard to treat areas. These are powerful meds with potential side effects (thin skin, broken blood vessels, and more) and should be used carefully under a medical doctor's supervision. Also,the use of topical steroids on brown skin can create lightening, which may take time to repigment, says Dr. Gohara. Its always important to apply steroids directly on, not all around, lesions or areas of concern.

The NPF advises not to use a topical steroid for longer than three weeks without consulting a doctor, as well as to avoid stopping the use of one suddenly because that can cause a flare-up of your psoriasis. Another reason to use these under the care of a physician: Topical steroids can be absorbed via the skin and have an impact on internal organs when used for a long period of time or over a wide area of skin.

These prescription treatments also come in various forms not just creams, lotions and ointments, but also gels, foams, and more. In some medications, vitamin D is combined with a steroid. Like other treatments, meds with vitamin D slow down the pace of your skin cells' growth. (Depending on the specific medication, side effects can include skin irritation, stinging, burning, itching or excessive calcium in the urine.) One advantage of vitamin D creams is they dont run the risk of causing skin atrophy a very real side effect of chronic topical steroid use, says Dr. Gohara. But they can be more irritating. Generally, systemic side effects are rare, yet hypercalcemia is a theoretical risk, and your doctor may opt to have you get blood tests.

Vitamin A treatments

A topical retinoid, vitamin A is the active ingredient in prescription medication that comes in the form of a cream, gel, or foam. It also works by slowing the growth of skin cells. When using it, the plaques of psoriasis may turn bright red before clearing up. Side effects here also include skin irritation; the medication increases the risk of sunburn as well, so its critical to use sunscreen to protect your skin when using these meds.

Coal tar

This ingredient is found in different strengths in various treatment forms, including shampoo. It can be found in OTC products in its weaker strength and by prescription for stronger versions. Like other products, coal tar slows the growth of skin cells, but it can be stinky and irritating, and can stain your bedding and clothes (as well as blond hair).

Heres one of the challenging things about treating psoriasis: Your body can build up a tolerance to a certain medications, so something that seemed magical in its ability to bring you relief could suddenly stop working. On the other hand, a treatment that didnt work for you years ago could suddenly work wonders.

Thats why trial and error is a necessary part of psoriasis treatment. Finding the right treatment for psoriasis is much like finding the right partner. It may take some 'dating' until the right one finally comes along, says Dr. Gohara. Some may work for a bit, but then efficacy fizzles. Topical steroids are the most common culprit of this phenomenon, although it may happen with other topical or systemic medication as well.

According to the National Psoriasis Foundation, its key to moisturize daily it can lessen the itchy redness. They recommend that you use fragrance-free products and soaps that moisturize rather than dry you out, skip the way-hot shower (keep it lukewarm), and rub on moisturizer right after showering. The NPF recommends these OTC creams, based on information theyve heard from dermatologists while emphasizing that none of them are stand-ins for treatment from a healthcare provider. Still, theyre all deeply moisturizing and may improve some pesky symptoms such as flaking and itching:

Anti-Itch Concentrated Lotion with Calamine and Triple Oat Complex

This creamhas anti-inflammatory and antioxidant ingredients.

Moisturizing Cream for Psoriasis

CeraVe developed this with dermatologists to moisturize skin and rebuilt the skin barrier.

Hydra Therapy, Itch Defense Moisturizer

A shea butter lotion, it's designed to be used right after a shower.

Psoriasis Medicated Treatment Gel

$42.29

This gelhas salicylic acid to work on scales, itching, and dryness.

Skin Calming Intensive Itch Relief Lotion

With menthol and oatmeal, the lotion is especially good for nighttime itching, according to the manufacturer.

Ultimate Multi-Symptom Psoriasis Relief Cream

$25.90

A soothing cream with salicylic acid and a bunch of moisturizers.

Intense Skin Repair Body Lotion

$28.48

The manufacturer says this deeply moisturizing lotion lasts for 24 hours to help repair skin.

Medicated Moisturizing Psoriasis Cream

A salicylic acid cream that also contains aloe and shea butter.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Go here to see the original:
The Best Creams for Psoriasis - Over-the-Counter and ...

Psoriasis and psoriatic arthritis are both autoimmune disorders: They result from the immune system mistakenly attacking the body. Another autoimmune disorder, Hashimotos thyroiditis, can cause hypothyroidism.

Doctors and researchers believe that a person with one autoimmune condition, such as psoriasis or psoriatic arthritis, may have a higher likelihood of developing another autoimmune condition, such as Hashimotos thyroiditis.

Also known as Hashimotos disease, this condition causes the immune system to attack the thyroid gland, preventing it from making enough thyroid hormone. Hypothyroidism refers to having too little thyroid hormone in the body.

Below, learn more about the relationship between these autoimmune disorders.

Psoriasis is an autoimmune disorder that causes scaly, itchy patches of skin to form around a persons trunk, large joints, and other areas of the body. It affects about 24% of the population.

Psoriatic arthritis is a type of arthritis that can occur in people with psoriasis. About 30% of people with psoriasis also develop this form of arthritis. It is not possible to have psoriatic arthritis without psoriasis.

This inflammatory type of arthritis causes symptoms such as joint pain, swelling, and stiffness. If a person does not receive treatment, psoriatic arthritis can eventually lead to joint damage and mobility issues.

Hypothyroidism occurs when the thyroid gland does not make enough thyroid hormone to meet the bodys needs. The body uses this hormone to keep the brain, heart, and muscles functioning correctly. It also helps the body effectively burn calories for energy and warmth.

There are various causes of hypothyroidism, including Hashimotos disease, surgical removal of the thyroid gland, and other treatments for other health issues.

Hypothyroidism is not closely associated with psoriasis generally or psoriatic arthritis in particular. However, research indicates that a person with psoriasis may have a higher chance of developing hypothyroidism.

A 2017 study found that people with both psoriasis and psoriatic arthritis had a higher likelihood of developing this thyroid condition.

Another study from 2017 and one from 2018 found similar results: People with psoriasis had a higher likelihood of developing thyroid disease, such as hypothyroidism, compared with the general population.

Also, a 2019 review of studies found that people with psoriasis had a much higher prevalence of Hashimotos disease than those without psoriasis.

While there is a need for more studies with more participants, many researchers currently recommended that doctors regularly screen people with psoriasis for thyroid conditions.

Psoriasis and psoriatic arthritis are autoimmune conditions. While having psoriasis may increase the chances of developing hypothyroidism, one condition is not a sign of the other.

The American Thyroid Association report that common symptoms of hypothyroidism include:

These symptoms are relatively nonspecific and can stem from various causes. If a person experiences these symptoms, the doctor can check for hypothyroidism with a simple blood test.

If a person has hypothyroidism, the doctor prescribes a synthetic version of thyroid hormone. This medication should not affect psoriasis or psoriatic arthritis.

However, as the American Academy of Dermatology Association note, other medications can trigger new or worsening psoriasis symptoms, in periods called flare-ups.

If a medication has this effect, psoriasis symptoms typically get worse after about 23 weeks of starting the medication.

Some medications that may trigger a flare-up include:

Speak with a doctor before trying a new treatment, and let the doctor know if psoriasis symptoms worsen or new ones appear.

Myxedema is a skin condition that occurs in relation to advanced hypothyroidism. It develops when a person has the thyroid disorder and does not receive treatment for a long period.

A myxedema rash does not resemble psoriasis. Instead, it appears as waxy, swollen, thickened areas of skin.

Without medical intervention, myxedema can cause a life threatening coma. Anyone who may have this issue should receive prompt medical care.

Anyone with psoriatic arthritis or another form of psoriasis should speak with a doctor about the risk of developing another autoimmune disorder, such as Hashimotos disease.

Also, let the doctor know about any new or worsening psoriasis symptoms or symptoms of hypothyroidism.

In addition, contact the doctor if treatments are no longer controlling the symptoms. The doctor can adjust the treatment plan accordingly.

Research suggests a potential link between psoriasis, including psoriatic arthritis, and hypothyroidism. However, having psoriasis does not guarantee that hypothyroidism will also develop.

Work closely with a doctor to treat any form of psoriasis and let them know if any symptoms of an underactive thyroid develop.

Excerpt from:
Is there a link between psoriatic arthritis and hypothyroidism? - Medical News Today

BARCELONA, Spain and COPENHAGEN, Denmark, Feb. 17, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora Cream for treatment of plaque psoriasis. In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to significant sales milestone payments and double-digit royalties on the European sales of Wynzora Cream. Almirall and MC2 Therapeutics partner to make Wynzora Cream a leading topical product for treatment of plaque psoriasis in Europe - a market, which currently is more than 25 million units in sales volume annually2. The market represents a significant opportunity for Wynzora Cream as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of share of volume and annual sales of more than $300 million.2

Wynzora Cream (50 g/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th July 2020. Wynzora Cream is currently under review in Europe supported by two Phase 3 trials1, including an EU head-to-head trial against active comparator Dovobet/Daivobet Gel. The Physician Global Assessment (PGA) treatment success defined as a minimum two-point decrease in the PGA score to clear or almost clear disease at Week 8 was 51% for Wynzora Cream vs. 6% for vehicle (p<0.0001). The treatment satisfaction score using the Psoriasis Treatment Convenience Scale (PTCS) was superior compared to Dovobet/Daivobet Gel. Using MC2 Therapeutics' PAD Technology, Wynzora Cream was uniquely designed to provide patients a new treatment option in their daily routines by combining the three essentials of a topical therapy in one single product namely high efficacy, a favorable safety profile and convenience of use.

Mike Mcclellan, Chief Financial Officer (CFO) and interim Chief Executive Officer (CEO) said: "We are thrilled with this agreement with MC2 Therapeutics. Wynzora Cream has demonstrated significant improvements in the skin clearance of psoriasis patients. It is the perfect addition to our growing psoriasis portfolio, which includes multiple treatment options, covering the whole spectrum of the disease. We are delighted that soon we will be able to offer this novel topical treatment to European dermatologists and their patients."

Jesper J. Lange, CEO of MC2 Therapeutics, commented: "We are excited to partner with Almirall, an established company with deep expertise in dermatology and psoriasis and with the focus to improve patients' needs. Bringing together Almirall's excellence in commercial operations and MC2 Therapeutics' commitment to ensure a global roll-out of Wynzora Cream we will, upon approval, ensure a strong launch of Wynzora Cream for the benefit of the many patients living with plaque psoriasis and for the healthcare practitioners who provide care. We believe that the unique combination of compelling clinical efficacy, a favorable safety profile and treatment convenience are key components to treatment adherence and overall better patient satisfaction in topical treatment of plaque psoriasis in a real-world setting."

About Plaque Psoriasis Psoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of plaque psoriasis on people's lives can be immense as it affects the appearance of the skin with red, scaly plaques. Psoriasis affects people of all ages, and in all countries. The reported prevalence of psoriasis in Europe varies from 0.6% to 6.5% with an average of approximately 3% of the population3,4making psoriasis a serious global problem with more than 100 million individuals affected worldwide.5The flares of psoriasis can be unpredictable and significant comorbidities are common, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.4

About Wynzora CreamWynzora Cream (50 g/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) is under review in Europe as a topical treatment of plaque psoriasis in adults. Wynzora Cream is based on PAD Technology, enabling an aqueous cream formulation of both calcipotriol and betamethasone as dipropionate and optimal delivery of active ingredients into the target tissue. Wynzora Cream was approved in the US by the FDA on 20th July 2020.

References:1Clinical trial IDs: NCT03802344 and NCT03308799 on Clinicaltrials.gov 2IQVIA MIDAS 3Chandran, V., and S.P. Raychaudhuri. 2010. 'Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis', J. Autoimmune, 34: J314-J21 4Schafer, T. 2006. 'Epidemiology of psoriasis. Review and the German perspective', Dermatology, 212: 327-37 5WHO Global report on Psoriasis 2016

SOURCE Almirall, S.A.

Read the original here:
Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora Cream for treatment of...

Psoriasis treatment marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 15.09 billion by 2027 growing with the CAGR of 7.35% in the above-mentioned forecast period. Not having any specific effective and leading treatment will help in driving the growth of the psoriasis treatment market.

Psoriasis treatment market research report utilizes the graphs and charts which turns it into more visually appealing. This makes available the best way to the users to understand customer and thus increase their satisfaction by answering the needs and expectations. It also helps to see what factors are influencing the business, where the brand is situated, and get the temperature of the market before a product is launched. Once all the market analysis and studies are done, it is time to present them efficiently, so as to onboard everyone and make the right decisions for the business strategy market research reports are the key partners in the matter.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-psoriasis-treatment-market&kb

The major players covered in the psoriasis treatment market report are Eli Lilly & Company, Pfizer Inc., Janssen Global Services LLC, Celgene Corporation, Takeda Pharmaceutical Company Limited, Novartis International AG, Amgen Inc., Biogen Inc., Abbvie Inc., AstraZeneca, Boeringer Ingelheim International GmbH, Biogen, Johnson & Johnson Services Inc., Merck & Co. Inc., Sun Pharmaceuticals Industries Ltd., Stiefel Laboratories, UCB S.A., LEO Pharma, Cipla Inc., Rowan Bioceuticals, Glenmark Pharmaceuticals, and Win-Medicare Pvt. Ltd., among other domestic and global players.

Global Psoriasis Treatment Market Scope and Market Size

Psoriasis treatment market is segmented on the basis of drug class, type, route of administration, application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Enquire Here Get customization & check discount for report @:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-psoriasis-treatment-market&kb

Key questions answered in the Global Psoriasis treatment Market report include:

Table of Contents:

Request for Detailed TOC:https://www.databridgemarketresearch.com/toc/?dbmr=global-psoriasis-treatment-market&kb

Major Insights of the Report

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Global Psoriasis Treatment Market Including Business Growth Statistics, New Opportunities And Competitive Outlook By Celgene Corporation, Takeda...

Phototherapy Device Market: Introduction

Read Report Overview - https://www.transparencymarketresearch.com/phototherapy-device-market.html

Key Drivers, Restrains, and Opportunities of Global Phototherapy Device Market

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81376

Request for Analysis of COVID-19 Impact on Phototherapy Device Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81376

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=81376

North America to Capture Major Share of Global Phototherapy Device Market

Pre Book Phototherapy Device Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=81376&ltype=S

Key Players Operating in Global Phototherapy Device Market

The global phototherapy device market is highly consolidated due to the presence of key players. A large number of manufacturers hold a major share in their respective regions. Demand for products to treat diseases is increasing in emerging as well as developed markets. Growth strategies adopted by leading players are likely to drive the global phototherapy device market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Link:
Phototherapy Device Market: Rising prevalence of skin diseases is expected to drive the market - BioSpace